REVB — Revelation Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $3.26m
- -$3.28m
Annual cashflow statement for Revelation Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -2.53 | -12 | -10.8 | -0.12 |
| Depreciation | ||||
| Non-Cash Items | 0.029 | 0.523 | 0.316 | -8.17 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 1.08 | 0.356 | -0.731 | 0.982 |
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Cash from Operating Activities | -1.42 | -11.1 | -11.2 | -7.29 |
| Capital Expenditures | 0 | -0.132 | 0 | — |
| Purchase of Fixed Assets | ||||
| Cash from Investing Activities | 0 | -0.132 | 0 | — |
| Financing Cash Flow Items | — | — | 11.5 | 0 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 5.91 | 8 | 15.2 | 14 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 4.49 | -3.22 | 3.98 | 6.74 |